Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin (2016 - 2025)

Historic FCF Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 52.54%.

  • Enanta Pharmaceuticals' FCF Margin rose 799400.0% to 52.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.24%, marking a year-over-year increase of 937500.0%. This contributed to the annual value of 49.24% for FY2025, which is 937500.0% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' FCF Margin stood at 52.54%, which was up 799400.0% from 94.74% recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year FCF Margin high stood at 94.74% for Q2 2025, and its period low was 181.45% during Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median FCF Margin value was 121.33% (recorded in 2023), while the average stood at 106.54%.
  • In the last 5 years, Enanta Pharmaceuticals' FCF Margin tumbled by -1179300bps in 2022 and then soared by 2114900bps in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' FCF Margin (Quarter) stood at 49.31% in 2021, then plummeted by -234bps to 164.5% in 2022, then increased by 13bps to 143.17% in 2023, then dropped by -5bps to 150.63% in 2024, then soared by 65bps to 52.54% in 2025.
  • Its FCF Margin stands at 52.54% for Q3 2025, versus 94.74% for Q2 2025 and 107.37% for Q1 2025.